Who’s Going to CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

315 organizations and 536 people on the program at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, a ~1,700-person, evenly mixed industry & academic meeting of Alzheimer’s trial sponsors, trialists and biomarker teams. As of Oct 8, 2026.

Showing 1–3 of 315 organizations

Organization	CTAD 2026 Attendance
Mass General Brigham Boston, Massachusetts
massgeneralbrigham.org Hospitals & health systems Boston health system that includes Massachusetts General and Brigham and Women's hospitals; runs large Alzheimer's research and trial programmes.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue PUFA Trial Ancillary Biomarker Study: n-3 polyunsaturated fatty acids lower plasma soluble ICAM-1 and NfL in older adults with cerebral small vessel disease (P014) Other mechanisms and targets · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Baseline probable CAA phenotype, lobar microbleeds, and multispot white matter hyperintensities predict clinically consequential ARIA during anti-amyloid therapy (P071) PET and MRI imaging · Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Point-of-Care Low-Field MRI for Monitoring ARIA-E and Pseudoatrophy During Anti-Amyloid Therapy (P087) PET and MRI imaging · Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Outpatient Medications and Risk of Amyloid-Related Imaging Abnormalities in a Memory Clinic Population Receiving Anti-Amyloid Therapy (P098) Anti-amyloid and anti-tau therapies · Real-world data and access Talk Mon Nov 16 4:35pm Plasma p-tau217 outperforms neuroimaging biomarkers in predicting the risk of cognitive impairment in a multi-cohort study Blood and CSF biomarkers · Prevention and early disease Talk Tue Nov 17 10:20am Sex Differences in Plasma p-tau217, Amyloid-β, and Tau-PET in Cognitively Unimpaired Adults from the AHEAD International Screening Cohort Blood and CSF biomarkers · PET and MRI imaging Poster Wed Nov 18 7:15am–5:30pm SLIM (Single-Arm Lead-In with Multiple Assessments): Optimizing Repeated Biomarker Assessments to Improve Statistical Power in Clinical Trials (P229) Trial design and endpoints · Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Plasma brain-derived p-tau217/total-tau ratio outperforms plasma p-tau217 for detecting autopsy-confirmed Alzheimer’s neuropathology, including in early-disease and mixed-pathology cases (P255) Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm MPS-AD: Human iPSC-Derived Microphysiological Systems Capture Molecular Heterogeneity and Enable Therapeutic Screening in Alzheimer’s Disease (P336) Other mechanisms and targets Talk Wed Nov 18 4:00pm Beyond amyloid and tau: Hippocampal volume and cognitive performance in the AHEAD-345 Study screening cohort PET and MRI imaging Poster Thu Nov 19 7:15am–5:00pm Association of MAO-B Inhibitors with Cognitive Decline Over 10 Years in Parkinson’s Disease: A Quasi-Experimental Study (P381) Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Remote Multiday Digital Cognitive Assessment Among Patients Evaluated for Anti-Amyloid Treatment: Feasibility and Clinical Correlates (P435) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Associations between Alzheimer’s disease biomarkers and multiday digital cognitive performance in older adults at elevated vascular risk (P444) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Cognitive Benefit from the Structured Lifestyle Intervention in U.S. POINTER Replicated and Extended with Digital Cognitive Outcomes (P447) Prevention and early disease · Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Remote Odor Percept Identification as a Scalable Marker of Alzheimer’s Disease (P459) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Longitudinal digital speech assessment in progressive supranuclear palsy (P461) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Automated verbal fluency as a digital cognitive biomarker in progressive supranuclear palsy: a longitudinal study (P462) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Higher baseline mean arterial pressure predicts moderate-to-severe ARIA and ARIA-related treatment discontinuation in a real-world population (P468) Anti-amyloid and anti-tau therapies · Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Evaluation of Cognitive and Functional Outcomes of Lecanemab Treatment Using Real-World Data (P473) Anti-amyloid and anti-tau therapies · Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Cognitive Testing as a Predictor of Anti-Amyloid Therapy Eligibility: An Exploratory Analysis of Real-World Memory Clinic Data (P497) Real-world data and access · Anti-amyloid and anti-tau therapies
Massachusetts General Hospital Boston, Massachusetts
massgeneral.org Hospitals & health systems Harvard teaching hospital in Boston with an NIA-funded Alzheimer's Disease Research Center and the Martinos Center for brain imaging.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Five-year phase II BCG immunotherapy trial for Alzheimer’s disease prevention in diabetes: Impact of APOE ε4 status on p-tau217 and Aβ42/40 (P042) Prevention and early disease · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Lithium Orotate for Early Stages of Alzheimer Disease and Related Dementias: Design and Methods of a Placebo-Controlled Dose-Ranging Pilot Trial (P056) Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue A practical correction for non-specific [18F]MK-6240 uptake to improve tau PET quantification for early detection (P088) PET and MRI imaging Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Tau PET spatial patterns for trial-relevant measurement of tau progression in preclinical AD: AHEAD-3/45 and HABS (P089) PET and MRI imaging · Prevention and early disease Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Rapid tau proliferation at different amyloid stages based on initial tauopathy (P101) PET and MRI imaging Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Predictors of longitudinal amyloid clearance due to lecanemab treatment: A preliminary report from a real-world clinical cohort (P107) Anti-amyloid and anti-tau therapies · PET and MRI imaging · Rising Stars Showcase Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Predictors of ARIA-H in A4 Study: White matter hyperintensity and APOE ɛ4 selectively influence lobar microhemorrhages (P108) PET and MRI imaging · Anti-amyloid and anti-tau therapies · Rising Stars Showcase Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Limited social connection and dementia risk: candidate biological processes with therapeutic implications (P158) Prevention and early disease · Other mechanisms and targets Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Sex matters in Alzheimer’s disease: Gaps and recommendations for clinical trials (P166) Trial design and endpoints Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue A common Alzheimer’s disease-linked HLA-DRB1 genetic variant potentiates tau-associated microglial reactivity (P167) Other mechanisms and targets Talk Tue Nov 17 2:20pm Detecting cognitive decline in preclinical AD over 1.5 years using digital cognitive assessments Digital assessment and AI · Prevention and early disease Poster Wed Nov 18 7:15am–5:30pm Utility of plasma pTau217 for cohort enrichment and outcome measurement in prevention trials (P284) Blood and CSF biomarkers · Prevention and early disease Poster Wed Nov 18 7:15am–5:30pm Domain-Specific CSF Proteomic Signatures of Cognitive Function in the ALBION Cohort (P315) Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Amyloid Pathology Modulates the Proteomic Architecture of Global Cognition (P316) Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Portable, Low-field MRI Combined with Machine Learning Segmentation for Cognitively Impaired Individuals (P385) PET and MRI imaging · Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Longitudinal Game-Based Monitoring in Older Adults With and Without Cognitive Impairment Using MIND GamePack (P438) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Infusion-Related Reactions Associated with Anti-Amyloid Monoclonal Antibodies: A Real-World Comparison of Lecanemab and Donanemab (P503) Anti-amyloid and anti-tau therapies · Real-world data and access Talk Thu Nov 19 11:35am Cognitive change across the healthy adult lifespan, ages 36 to 108: Associations with modifiable risk factors and ADRD plasma biomarkers Prevention and early disease · Blood and CSF biomarkers Talk Thu Nov 19 2:20pm Distinct baseline topographies and short-interval spatiotemporal spread of [18F]MK-6240 tau PET in preclinical AD PET and MRI imaging
Washington University in St. Louis St. Louis, Missouri
washu.edu Universities & institutes Leads the DIAN network and DIAN-TU trials in inherited Alzheimer's disease, and runs the Knight Alzheimer Disease Research Center.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Senolytic Therapy in Early Alzheimer’s Disease: A Randomized Phase II Trial Suggests Effects on CSF Tau Biomarkers (P036) Other mechanisms and targets · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Spatiotemporal Emergence and Longitudinal Progression of Tau-PET Pathology in Autosomal Dominant Alzheimer Disease: Implications for Prevention Trial Design (P085) PET and MRI imaging · Prevention and early disease Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue GPND-AI Treatment: A Trajectory Monitor for Treatment Responses (P123) Digital assessment and AI Session Mon Nov 16 4:50pm–5:30pm Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab Anti-amyloid and anti-tau therapies · PET and MRI imaging Talk Mon Nov 16 5:30pm Agentic Artificial Intelligence in Alzheimer’s Disease Clinical Trials: From Data-Driven Discovery to Adaptive Design Optimization and Statistical Validation Digital assessment and AI · Trial design and endpoints Talk Tue Nov 17 3:30pm Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer’s Disease Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Quantum Capacitance Electrochemical Biosensor for the Rapid and Ultrasensitive Detection of p-tau217 and MTBR-tau243 (P257) Blood and CSF biomarkers Talk Wed Nov 18 9:15am Estimating 15-Year absolute risk of cognitive impairment in cognitively unimpaired older adults with Alzheimer disease biomarkers based on amyloid PET or plasma %p-tau217 Prevention and early disease · Blood and CSF biomarkers Talk Wed Nov 18 2:25pm Calibrated age of onset for amyloid positivity from plasma %p-tau217 leads to better design and improved representation of Black Americans in Alzheimer disease clinical trials: Simpson’s paradox Blood and CSF biomarkers · Trial design and endpoints Talk Wed Nov 18 4:45pm Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer’s Disease Progression Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Prognostic versus propensity-score covariates for trial efficiency across the Alzheimer’s disease spectrum: an evaluation in dominantly-inherited and preclinical AD (P377) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Symmetric Centipolar Normalized Score (SCeNS): a standardization framework for fluid marker cross-comparability in Alzheimer’s disease (P383) Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Listening Before Recruiting: Community Listening Sessions to Improve Alzheimer’s Research Engagement (P387) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Smart Triage for Amyloid-Targeting Therapies (STATT) (P499) Real-world data and access · Anti-amyloid and anti-tau therapies Talk Thu Nov 19 1:05pm Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Instantly find 20 buyers from organizations at CTAD 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

When and where is CTAD 2026?

19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference runs November 16–19, 2026, at Boston Marriott Copley Place in Boston, MA.

Where is the CTAD 2026 program?

This guide lists every organization on the CTAD 2026 program with its sessions; the full program is on the official website.

How do I register for CTAD 2026?

Fees and registration are on the organizer's registration page.

What is CTAD 2026?

CTAD 2026 is the 19th Clinical Trials on Alzheimer’s Disease conference, held November 16–19, 2026 at the Boston Marriott Copley Place in Boston. It is a single-room meeting for Alzheimer’s clinical research: drug developers, academic trialists, regulators and the biomarker, imaging, digital and trial-services companies that support their studies, with sessions on anti-amyloid and anti-tau therapies, blood biomarkers, imaging, trial design and prevention.

What is in this guide?

Every organization we can place at CTAD 2026: the employers of the 536 people on the public program — speakers, symposium chairs and poster presenters across 614 program rows, 516 of them posters — and the 33 sponsors with their level (1 Ultimate, 4 Platinum, 5 Gold, 23 Silver). 315 organizations in one list. A talk or poster counts one person: a poster’s named presenter, or an oral communication’s first author (the program names no presenter for those), never a co-author. People appear as a role and a count, never by name.

Where does this list come from?

Three public pages from the organizer: the final program PDF (sessions and the full poster list), the poster list PDF and the sponsor page. Which organization each printed affiliation names, and what kind of organization it is, was judged from that text; short descriptions state what is well established about an organization. Nothing here requires a login.

How are organizations typed?

Universities and research institutes; hospitals, health systems and clinical trial sites; drug developers (large pharma and biotech); vendors (biomarker and diagnostics companies, digital assessment and AI companies, CROs and trial services, consultancies); and government agencies, foundations and non-profits. The topic filters are judged from each talk’s and poster’s title and the poster list’s own sections.

How current is it?

Pulled from the program, the poster list and the sponsor page on October 8, 2026, about six weeks before the meeting. CTAD publishes no booth numbers or attendee list, and late-breaking sessions can still be added.

Why are there no names?

This guide is about which organizations are in the room, not which people. It never publishes a person’s name.

Organizations with their own page

136 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction